Healthcare Startup Due Diligence: A Physician Investor Framework

Bottom line. Healthcare diligence is not simply conventional venture diligence with a regulatory checklist attached. A defensible investment thesis must connect the product’s intended use, evidence, regulatory pathway, payment mechanism, workflow fit, compliance posture, and financing needs into one coherent chain.

Key takeaways

• Start with the clinical claim and intended use. Every later question—trial design, regulatory pathway, coding, pricing, sales process, and liability—depends on what the product actually promises to do.
• Separate regulatory authorization from evidence of clinical or economic value. FDA clearance or approval answers a regulatory question; it does not automatically establish payer coverage, physician adoption, or commercial durability.
• Test reimbursement at the patient, provider, code, setting, and payer level. “Reimbursable” is not a complete business model.
• Treat physician relationships as both an asset and a compliance risk. Advisory compensation, equity, referrals, purchasing influence, and federal-program business require careful legal review.
• Use source documents and reproducible checks. A data room narrative should be reconciled against public databases, contracts, protocols, security assessments, and cap-table records.

Why healthcare diligence must be integrated

A healthcare startup can have compelling technology and still fail because its evidence does not support the marketed claim, its regulatory pathway is longer than assumed, its target customers cannot obtain payment, its workflow creates uncompensated burden, or its growth model depends on legally sensitive referral relationships. These risks interact rather than sit in separate workstreams.

The practical objective is therefore not to produce independent “clinical,” “regulatory,” and “commercial” memos. It is to test whether the company can move from a defined patient problem to lawful adoption, measurable benefit, sustainable payment, and a financing plan that survives the time required to reach those milestones.

The seven-domain diligence framework

1. Define the claim before judging the evidence

Write the company’s claim in a testable sentence: for a specified population and setting, the product changes a specified outcome compared with a relevant alternative over a stated time horizon. If management cannot agree on this sentence, diligence is premature because regulatory, trial, and reimbursement assumptions may be built around different products.

Distinguish four layers: technical performance, clinical validity, clinical utility, and economic value. A model may predict accurately yet fail to improve decisions. A device may change a surrogate without improving outcomes that patients or payers value. A service may improve outcomes but require staffing or integration costs that erase the customer’s return.

Ask for a claim-to-evidence matrix linking every material slide-deck assertion to a source, study population, comparator, endpoint, confidence interval, limitations, and publication status. Treat press releases, conference abstracts, and retrospective internal analyses as useful signals—not substitutes for complete evidence.

2. Reconstruct the evidence, including what is missing

Evaluate study design against the commercial claim. Review enrollment criteria, baseline balance, comparator selection, missing data, multiplicity, endpoint adjudication, follow-up, protocol deviations, adverse events, and whether the analysis was prespecified. Examine absolute effects and uncertainty, not only relative effects or p-values.

External validity matters commercially. A result from expert centers may not transfer to community practice; a narrowly selected population may not resemble the payer’s beneficiaries; and a workflow supported by research coordinators may not survive routine deployment. CMS describes evidence appraisal in terms that include validity, clinical relevance, and the weight or magnitude of effect—useful dimensions for investors as well as coverage reviewers.[1]

For applicable trials, reconcile the data room with ClinicalTrials.gov. FDAAA 801 and 42 CFR Part 11 assign registration and results-reporting responsibilities to a responsible party for covered trials.[2] Compare registered endpoints, enrollment, dates, and submitted results with manuscripts and company claims. Missing or delayed results deserve a documented explanation.

3. Verify the regulatory pathway from primary records

Do not accept “FDA registered,” “FDA listed,” “510(k) exempt,” “cleared,” and “approved” as interchangeable. Determine whether the product is regulated, its classification and product code, its intended use, and the submission type required before marketing. FDA explains that many Class II devices use 510(k), novel low-to-moderate-risk devices may use De Novo, and high-risk devices generally require PMA.[3]

The evidentiary standard differs by pathway. A 510(k) establishes substantial equivalence to a legally marketed predicate, while PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness for the intended use.[4] The investment memo should therefore identify exactly what the agency decided—not infer more from the decision than it supports.

Independently search FDA databases for the company, device, product code, predicates, recalls, adverse-event signals, and relevant warning letters. FDA’s Total Product Life Cycle resources combine premarket and post-market sources, including recalls and MAUDE, at the product-code level.[5] Review the actual labeling and decision summary; commercial claims that exceed authorized labeling can create enforcement and reimbursement risk.

4. Build reimbursement from the claim outward

Coverage, coding, and payment are distinct. Identify the beneficiary, covered benefit category, site of service, billing entity, code, payment rate, documentation requirements, and payer. Then test whether the product changes an existing payment flow, creates uncompensated work, or depends on a new coverage decision.

CMS states that Medicare coverage requires an item or service to be reasonable and necessary and within a Medicare benefit category. National coverage decisions use an evidence-based process; where no national policy exists, Medicare Administrative Contractors may make local coverage determinations.[6] That makes geography, contractor policy, and setting of care material to revenue forecasts.

Pressure-test management’s model with observed claims, denials, collection timing, contractual rates, and patient cost sharing. For technologies with immature evidence, consider whether coverage could be limited to additional data collection. CMS’s Coverage with Evidence Development framework illustrates how access and evidence generation can be linked.[7]

5. Measure adoption with cohort economics, not logos

A signed pilot is not equivalent to repeatable demand. Build customer cohorts showing implementation time, activation, utilization, renewal, expansion, gross retention, net retention, and contribution margin. Separate paid deployments from free pilots and strategic agreements. Reconcile pipeline reports with executed contracts and invoices.

For clinician-facing products, map who chooses, uses, pays for, benefits from, and can block the product. Interview frontline users as well as executives. Quantify training, clicks, alert burden, integration work, staffing, and downstream utilization. A solution that improves a metric but adds uncompensated work may struggle even when clinicians like it.

6. Examine physician relationships, privacy, and security

Physician investors bring domain expertise and access, but ownership, advisory compensation, purchasing influence, and referrals can create overlapping conflicts. HHS OIG identifies the Anti-Kickback Statute, False Claims Act, Stark law, exclusion authorities, and Civil Monetary Penalties Law as central federal fraud-and-abuse laws for physicians. The Anti-Kickback Statute reaches remuneration intended to induce or reward federal-program referrals or business.[8] Obtain specialized legal review of the actual facts; do not rely on a generic “fair-market-value” label.

Map every category of health data, each system that receives it, the legal role of each party, and every onward disclosure. HIPAA may apply to covered entities and business associates, but being outside HIPAA is not the same as being outside health-privacy regulation. The FTC’s amended Health Breach Notification Rule expressly addresses many health apps and similar technologies not covered by HIPAA.[9]

Request the latest security risk analysis, remediation plan, penetration-test summary, incident log, business-associate agreements where applicable, subprocessors, backup and recovery evidence, cyber insurance, and security ownership. HHS describes risk analysis as foundational to identifying reasonable and appropriate safeguards for electronic protected health information.[10]

7. Connect milestones to financing and governance

Translate the operating plan into a milestone-based financing model. Regulatory submissions, clinical studies, evidence publication, coding applications, payer contracting, integration, and enterprise sales can each shift timing and cash needs. Build downside cases for a delayed regulatory decision, additional study, slower enrollment, lower reimbursement, longer procurement, and a financing round at a reduced valuation.

Reconcile the fully diluted cap table to charter documents, SAFEs, notes, warrants, option grants, side letters, pro rata rights, liquidation preferences, anti-dilution terms, information rights, and board approvals. Confirm founder and employee IP assignments. Private offerings also carry securities-law constraints; the applicable exemption and investor-qualification process should be reviewed with counsel.[11]

A practical investment-committee test

A strong healthcare investment memo should make the dependency chain explicit:

1. Clinical thesis. Which patient or system outcome changes, for whom, compared with what, and by how much?
2. Evidence thesis. What evidence supports that claim today, what uncertainty remains, and what study closes the gap?
3. Regulatory thesis. What may legally be marketed now, what authorization is next, and what claims will the labeling permit?
4. Payment thesis. Who pays, under what mechanism, at what net rate, and what evidence or operational steps are required?
5. Adoption thesis. Why will the buyer purchase, the user adopt, and the organization renew after implementation burden is counted?
6. Compliance thesis. Can physician relationships, referral flows, claims, and data practices scale without creating unacceptable exposure?
7. Financing thesis. How much capital is required to reach the next value-inflecting milestone under a realistic downside case?

If one thesis depends on another being true, state the dependency. If a pivotal assumption cannot yet be verified, convert it into a dated diligence condition, financing milestone, governance right, or explicit reason not to invest.

Red flags that deserve escalation

• Regulatory terminology changes across the deck, data room, website, and sales materials.
• The company cites authorization but will not provide the decision letter, labeling, submission summary, or relevant agency correspondence.
• Clinical claims rely on a post hoc subgroup, surrogate endpoint, uncontrolled comparison, or unpublished internal analysis without appropriate caveats.
• Revenue projections assume broad reimbursement while evidence is limited to one payer, one code, one site of service, or temporary pilot funding.
• Physician equity or consulting payments overlap with referrals, purchasing decisions, trial enrollment, formulary influence, or federal-program business.
• Customer “logos” cannot be reconciled to paid deployments, utilization, renewal, and collections.
• Security documentation is limited to a badge or questionnaire with no scoped risk assessment, remediation record, or incident process.
• The base-case financing plan assumes every clinical, regulatory, and commercial milestone occurs on schedule.

Frequently asked questions

Does FDA clearance prove that a healthcare startup will be reimbursed?

No. FDA authorization and payer coverage answer different questions. Investors must separately verify benefit category, coverage policy, coding, payment rate, documentation requirements, and site of service.

What is the first document a physician investor should request?

There is no universal single document, but a claim-to-evidence matrix is an efficient starting point because it exposes which commercial assertions rest on regulatory decisions, clinical data, economic models, or assumptions.

Are physician advisory shares automatically problematic?

No, but the facts matter. Compensation, fair-market value, actual services, referral influence, purchasing authority, and federal-program business should be reviewed by qualified counsel.

Is HIPAA compliance enough for a digital health company?

Not necessarily. The company may face HIPAA obligations, FTC requirements, state privacy laws, contractual duties, and cybersecurity expectations. Scope depends on the product, data flows, parties, and jurisdiction.

Should physician investors require every risk to be resolved before investing?

Early-stage investing necessarily involves uncertainty. The goal is to distinguish measurable risk from unsupported assumption, price the remaining uncertainty, and tie capital or governance protections to verifiable milestones.

Conclusion

Physician expertise is most valuable when it sharpens—not substitutes for—structured diligence. The disciplined investor begins with the intended clinical claim, traces it through evidence and regulation, tests whether payment and workflow support adoption, examines compliance and data practices, and then asks whether the financing plan can carry the company across the remaining gaps. The result is not certainty. It is a transparent investment thesis whose assumptions can be checked, monitored, and revised.

References

1. Centers for Medicare & Medicaid Services. National Coverage Determination Process & Timeline.
2. ClinicalTrials.gov. FDAAA 801 and the Final Rule.
3. U.S. Food and Drug Administration. How to Determine if Your Product is a Medical Device.
4. U.S. Food and Drug Administration. Device Approvals and Clearances.
5. U.S. Food and Drug Administration. Total Product Life Cycle for Medical Devices.
6. Centers for Medicare & Medicaid Services. Medicare Coverage Determination Process.
7. Centers for Medicare & Medicaid Services. Coverage with Evidence Development Guidance Document (2024).
8. HHS Office of Inspector General. Fraud & Abuse Laws.
9. Federal Trade Commission. Complying with the FTC’s Health Breach Notification Rule.
10. U.S. Department of Health and Human Services. Guidance on Risk Analysis.
11. U.S. Securities and Exchange Commission. Private Placements—Rule 506(b).

Editorial disclaimer: This article is for educational purposes only and does not constitute medical, legal, tax, accounting, or investment advice. Healthcare regulation and payment policy are fact-specific and change over time. Readers should consult qualified professionals and verify current primary sources before acting.